Detalhe da pesquisa
1.
Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice.
Cancer
; 127(12): 2015-2024, 2021 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33739457